GRI Bio, Inc. (GRI) vs Lexaria Bioscience Corp. (LEXX)

Over the past 5 years, LEXX outperformed GRI — -50.86% vs -95.39% annualized total return (price plus dividends).

A side-by-side comparison of GRI Bio, Inc. and Lexaria Bioscience Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — GRI vs LEXX

growth of $100 · dividends reinvested · last 6y
GRI -100.0% (-92.4%/yr)LEXX -97.7% (-46.6%/yr)LEXX compounded faster over this window
Log scale — wide-divergence pair
000001101001kStart $10020222023202420252026$0$2
GRI LEXX

Metrics side by side

Did LEXX beat GRI?

Over the past 5 years, LEXX outperformed GRI — -50.86% vs -95.39% annualized total return (price plus dividends).

Total return (annualized)

MetricGRILEXX
Total return (1Y)-96.44%-78.83%
Total return CAGR (3Y)-97.04%-41.44%
Total return CAGR (5Y)-95.39%-50.86%

GRI is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Frequently asked

Has LEXX beaten GRI?
Over the past 5 years, LEXX outperformed GRI — -50.86% vs -95.39% annualized total return (price plus dividends).

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.